Summary -Amiodarone treatment is associated with the occurrence of thyroid dysfunction. The aim was to determine the incidence of amiodarone-induced thyroid dysfunctions and the influence of gender, age, treatment duration, goiter, thyroid antibodies, thyroid echogenicity and family history on their appearance. Of 248 consecutive patients, 144 males and 104 females, referred to thyroid status screening, 16% were with clinical dysfunction, 21% with sub-clinical dysfunction and 63% were euthyroid. The presence of goiter and thyroid peroxidase antibodies were the significant individual predictive factors for the occurrence of clinical dysfunction, and in the multivariate regression model, the presence of goiter was a significant predictive factor with the prognostic value of 80%. For sub-clinical dysfunction, the significant individual predictive factors were female gender and the presence of goiter, as well as in the multivariate regression model, with the prognostic value of 74.5% for female gender and 77.5 % for the presence of goiter. It is necessary to check the thyroid status both before and during amiodarone treatment. Administration of other anti-arrhythmic drugs and/or more frequent check-ups of the thyroid status should be taken into consideration in patients at higher risk, i.e. women with positive thyroid peroxidase antibodies and goiter.
Introduction
One of the prominent characteristics of potent antiarrhythmic amiodarone is the high iodine content in a molecule. Each 200 mg tablet of amiodarone contains 75 mg of organic iodine. It has been shown that one of the reasons of thyroid dysfunction induction could be iodine overload in patients on chronic treatment, and another mechanism by which amiodarone can induce thyroid dysfunction is the direct cytoto-xicity of this drug itself [1] . This cytotoxic effect could be due to cytotoxicity of amiodarone itself, its meta-bolite desetylamiodarone, as well as iodine released through the amiodarone metabolism [2] .
Amiodarone-induced thyroid dysfunctions can occur in about 32% of treated patients [3] . The incidence of amiodarone-induced hypothyroidism (AIH) is reported to be 0.75%-10%, going even up to 29% and varying with the daily iodine ingestion [3] [4] [5] . AIH is more frequent in areas with sufficient and high iodine ingestion by food, more frequent among women and elder people [3, 6] . According to some reports, AIH occurs early during amiodarone treatment [3] . The incidence of amiodarone-induced thyrotoxicosis (AIT), reported up to date, is 0.003%-23%, most frequently 1%-5% [4, 5, 7] . AIT is more frequent in areas of low iodine ingestion by food and in men [6] . There are no reported regularities between the duration of amiodarone treatment and the occurrence of AIT [5] . As in AIH, the occurrence of AIT is not associated with the degree of iodine overload [3] .
The study was aimed at determining the incidence of amiodarone-induced thyroid dysfunction as well as the predictive value of gender, age, amiodarone therapy duration, positive family history, presence of goiter, thyroid echogenicity and the presence of antithyroid auto-antibodies for their occurrence.
Material and methods
The study sample consisted of 248 consecutive patients (144 males and 104 females, average age 63.4 years) referred to thyroid status screening because of amiodarone therapy. Their morpho-functional thyroid status was evaluated in relation to their age, gender, duration of amiodarone treatment and family history. All of the patients came from the Timočka Krajina region, known to have sufficient iodine supply. The average daily amiodarone dose was 200 mg, i.e. the maintaining dose which did not differ significantly among the examinees. Three control groups consisted of 30 to 34 consecutive examinees with spontaneous hyperthyroidism (7 males and 27 females, their average age being 44.44 years), spontaneous hypothyroidism (6 males and 26 females, average age 54.87 years) and euthyroid persons (5 males and 25 females, average age 43.5 years). The anamnestic data were collected and the physical examination was done, including the pulse rate measurement, determination of skin quality and presence of tremor, and body weight measurement. The thyroid size was estimated by palpation and the findings were described as the presence or absence of goiter, regardless of the degree and the type of enlargement. The free fraction thyroid hormone levels were measured by Access chemiluminoimmunoassay (CIA) with the normal value range for FT4 from 7.5 to 15 pmol/L and for FT3 from 3.8 to 6.0 pmol/L. The thyroid-stimulating hormone (TSH) level was measured by Access CIA with the normal value range from 0.34 to 4.5 mIU/L. Antithyroglobulin antibodies (TgAb) were measured by Access CIA with the normal value range up to 4.9 IU/ ml, anti-thyroperoxidase antibodies (TPOAb) were measured by Abbott AxSym micro particle enzymimmunoassay with the normal value range up to 12 IU/ ml. TSH receptor antibodies (TRAb) were measured by radio receptor assay (TRAK human, Brahms Diagnostica, GMBH, Germany) with the normal values up to 1.5 IU/L. The findings exceeding the upper value of normal range were considered positive. Thyroid echosonography was done using Toshiba Justvision 200 device with linear probe of 8 MHz. The echosonographical findings were classified as normal, without clinically important focal morphological changes, or as changed thyroid echogenicity, regardless of the type of changes. The criteria for AIH diagnosis were TSH greater than 10 mIU/L or TSH greater than 10 mIU/L and FT4 less than the lower level of normal range for assay. The criteria for AIT diagnosis were TSH less than 0.1 mIU/L and FT4 greater by 10 measuring units above the upper value of normal range for assay, or TSH less than 0.1 mIU/L, elevated FT4 and elevated FT3, and the presence of one or more symptoms and signs of thyrotoxicosis. Sub-clinical (SK), amiodarone-induced hypothyroidism was defined as the presence of serum TSH between 4-10 mIU/L, or TSH between 4-15 mIU/L and the normal value of FT4. Sub-clinical, amioda-rone-induced hyperthyroidism was defined as the state of TSH less than 0.1 mIU/L and normal, or slightly elevated FT4, for less than 10 measuring units above the upper value of normal range for assay and/or normal FT3 and the absence of symptoms and signs of thyrotoxicosis. The type of AIT was determined on the basis of additional diagnostic methods, Color Flow Doppler Sonography (CFDS), pertehnetate thyroid scintigraphy and MIBI thyroid scintigraphy, and revised according to the response to therapy (thioamides versus glucocrticoides), whose descriptions are beyond the scope of this article. The statistical analysis was done using c 2 test, student t test, Mann Whitney U test, univariate and multivariate logistic regression analysis.
Results
Of all examinees (248), 62.9% (156) were euthyroid (EU), 15.7% (39) had clinical thyroid dysfunction (TD) and 21.4% (53) had sub-clinical thyroid dysfunction (SKTD) (Graph 1). Table 1 shows the structure of examinees by their thyroid status, gender, age and amiodarone treatment duration.
The number of women was significantly higher in the control groups with spontaneous hyperthyroidism and hypothyroidism than in those with AIT and AIH (79.4% vs 40% and 81.3% vs 45.8%). The same is true when comparing the groups with amiodarone induced SKTD with the group of EU patients on amiodarone therapy (60.4% vs 35.3%). The positive family history was significantly more frequent in the patients with AIT type 2 and amiodarone induced SK hypothyroidism than in the EU patients on amiodarone therapy (25% and 20% vs 5.9%). Positive TgAb and TPOAb were significantly more frequent in the patients with spontaneous hypothyroidism than in those with AIH (100% vs 20% for TgAb and 100% vs 35.3% for TPOAb). Positive TRAbs were significantly more frequent in the patients with AIT type 1 than in the EU patients on amiodarone therapy (33% vs 1%). Changed thyroid echogenicity was significantly more frequent Goiter was significantly more frequently present in the patients with AIT (40%) and those with SKTD (24.5%) than in the euthyroid patients on amiodarone therapy (9%), and it was the most frequent among patients with AIT type 1 and AIT of mixed type (80% and 100%). A small but significant difference was found between the patients with AIT type 1 and AIT of mixed type according to amiodorane treatment duration, which was shorter in the mixed type. The interpretation of this result is rather cautious for there were only two patients with mixed type AIT. A statistically significant difference was found in the age of patients in the following groups: the AIH patients were significantly older than those with AIT of mixed type and the patients with spontaneous hypothyroidism; the AIT patients, regardless of the type, were significantly older than those with spontaneous hyperthyroidism; the EU patients on amiodarone therapy were significantly older than the control group of EU persons. Table 2 shows the analysis by univariate and multivariate regression of factors associated with the occurrence of amiodarone-induced SKTD, whereas Table 3 shows the prognostic value for prediction of SKTD occurrence, and Tables 4 and 5 show the analysis by univariate and multivariate regression of factors associated with amiodarone-induced TD occurrence and their prognostic value for prediction of TD occurrence. In univariate logistic regression, the significant predictors for SKTD occurrence were the presence of goiter and female gender, whereas both variables were the significant predictors in the multivariate model. In univariate logistic regression, the significant predictors for TD occurrence were the presence of goiter and positive TPOAb. In multivariate model, only the presence of goiter was a significant predictor.
Discussion

Incidence
Our research performed on 248 investigated patients on chronic amiodaron treatment coming from the region of Timočka Krajina, which has sufficient iodine supply, confirmed the earlier observed phenomenon suggesting the thyroid dysfunction induction by amiodarone. Sixteen percent of patients developed clinical thyroid dysfunction, while 21% developed some form of sub-clinical dysfunction. Incidence of AIH was 9.7% and 6% for AIT. These figures are similar to the ave-rage up-to-date reported incidence of clinical dysfunctions and in accordance with data on more frequent occurrence of AIH in the regions having sufficient iodine supply [4, 8] .
Influence of gender
When comparing the number of female and male examinees we noticed that there were 4 to 5 times more women than men in the control group of patients with spontaneous hypothyroidism, whereas their number was rather similar in the group with AIH. This finding is a bit different from the reported literature data [3, 5] . There are significantly more males in the group with AIT than in the control group with spontaneous hyperthyroidism. Also, there are more males than females in the group with AIT, but the difference is not statistically significant, these data being different from the reported data from the literature, where males are significantly more frequently affected by AIT [8, 9] . Our research has shown that females are significantly more affected by SKTD, especially sub-clinical hypothyroidism, compared to those who remained EU.
Influence of age
According to our findings, spontaneous thyroid dysfunctions occur in significantly younger patients than amiodarone-induced thyroid dysfunctions. This is in part due to the fact that cardiac arrhythmias as well as the need for anti-arrhythmic therapy increase with age [10, 11] . However, the average age of euthyroid patients on amiodarone therapy as well as of those who developed clinical or SKTD, was not statistically different. Thus, we can conclude that the age was not a significant determinant for thyroid dysfunction induction in patients treated with amiodarone. This is in accordance with already reported data [5] [6] [7] .
Influence of amiodarone treatment duration
We did not find any significant correlation between the duration of amiodarone treatment and the occurrence of clinical or sub-clinical dysfunction. There was only a small but statistically significant difference in the duration of amiodarone treatment between the patients with AIT type 2 and the patients with mixed form AIT -the latter occurred earlier during amiodarone therapy. According to some reports, AIH occurs early during amiodarone therapy, while others have not found a significant correlation [5, 6] .
Family history
There are reports showing that positive family history, i.e. thyroid diseases in family, is a risk factor for thyroid dysfunction induction by amiodarone [12] [13] [14] [15] ; however, other reports do not show any correlation between a positive family history and the occurrence of amiodarone-induced thyroid dysfunction [5, [16] [17] [18] . We have not found statistically significant difference in the frequency of positive family history in the majority of study groups. We have only found that ¼ of patients with AIT type 2 have a positive family history and this is significantly more frequent than in the EU patients on amioda-rone therapy (25% vs 5.9%). Also, 1/5 of patients with sub-clinical hyperthyroidism have a positive family history which is significantly more frequent compared to the euthyroid patients on amiodarone therapy (20% vs 5.9%). We think that a positive fa-mily history could be considered a risk factor for the occurrence of AIT type 2 and amiodarone-induced sub-clinical dysfunction.
Goiter
The presence of goiter is a risk factor for AIH and AIT type 1 [12, 14, [19] [20] [21] [22] . In about 10% of our EU patients on amiodarone therapy, some degree of thyroid enlargement and some morphological changes were found. Goiter was most frequent in the patients with AIT type 1 and mixed form of AIT, in about 80% of them, while none of the patients with AIT type 2 had goiter. In about ¼ of patients with SKTD and in about 1/5 of patients with AIH the goiter was found, while in other patients it was less frequent, up to 10%.
Thyroid echogenicity
In some reports, no significant correlation between changed thyroid echogenicity and amiodarone-induced thyroid dysfunction has been found [5] , but the reports on significant correlation are more frequent [23] [24] [25] .
Type 1 AIT is a classic iodine-induced thyrotoxicosis associated with true hyperthyroidism; thyroid hyperfunction is caused by the iodine overload and thyroid itself is changed in the manner of latent autonomy due to the existence of nodal disease or autoimmune disease. Type 2 AIT is a form of destructive thyroiditis caused by iodine itself, or more likely by amiodarone and its metabolite desethylamiodarone; the most cases develop in the previously normal thyroid gland, but small diffuse or nodous goiter could be present [19, 26, 27] .
We have observed that changed thyroid echogenicity, regardless of the kind of morphological changes, is significantly more frequent in the euthyroid patients on amiodarone therapy than in the control group of euthyroid persons. Such a finding is expected since the group of EU patients on amiodarone therapy is older, and thyroid changes cumulate with age. Some changes in the echostructure of the thyroid were found in 60%-80% of the examinees on amiodarone therapy, their frequency being similar in all study groups according to thyroid status, which is in accordance with other reports [5] . The estimation of thyroid morphology by ultrasound is more important in differential diagnosis of AIT type, where normal echostructure could exclude type 1 AIT. But changed thyroid echostructure does not exclude AIT type 2, since some morphological changes could be found even in these patients.
Thyroid immune status
Positive thyroid auto-antibodies are not rare even in general population of all ages and are five times more frequent in females than in males [28] . The role of amiodarone in the occurrence of thyroid autoim- [12, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Nevertheless, they could contribute to the progression of preexisted thyroid autoimmunity through the mechanism of increased antigen release due to direct thyroid cytotoxicity of the drug itself, or iodine released through its metabolism [3, 5] . When we compared all groups of interest according to the presence of positive TgAb, we found a significant difference only among the patients with spontaneous hypothyroidism, where TgAb were positive in 100%, and those with AIH, where TgAb were positive in only 1/5 of patients. Similarly, positive TPOAb were found much more frequently in the examinees with spontaneous hypothyroidism (100%) than in those with AIH, of whom about 35% had positive TOPAb. Positive TPOAb were significantly more frequently found in patients with AIT of all types, i.e. in 60% of them, than in the group of euthyroid patients on amiodarone therapy, where there were 20% patients with positive TPOAb. It is interesting that positive TPOAb were found in almost 1/3 of euthyroid control group subjects. TRAb was positive in about 8% of the AIT patients, being significantly less frequent than in the patients with spontaneous hyperthyroidism, of whom 80% were TRAb positive. In addition, positive TRAb was more frequent in the patients with AIT type 1 than in the euthyroid patients on amiodarone therapy, 33% vs 1%, while among other groups of interest there were no significant differences in TRAb positivity.
Predictive factors
Various studies have been aimed at determining possible predictive factors, such as gender, age, amiodarone treatment duration, thyroid immune status, regarding the occurrence of amiodarone-induced thyroid dysfunction [3] [4] [5] 23, 24, [30] [31] [32] [33] [34] .
We found that the presence of goiter and positive TPOAb were significant predictors for the occurrence of amiodarone-induced thyroid dysfunction in univariate regression analysis. When both factors were tested in the multivariate regression model, the presence of goiter was found to be a significant predictive factor, its prognostic value being about 80%.
The patients with amiodarone-induced sub-clinical thyroid dysfunciton are at a risk of developing clinical dysfunction, particularly in cases when amiodarone therapy is continued.
We have found that significant individual predictive factors for sub-clinical dysfunction were female gender and the presence of goiter, whose prognostic value in the multivariate regression model was also very high, being 74.5% and 77.5%, respectively.
Conclusion
It is necessary to check the thyroid status both before and during amiodarone treatment. Administration of other anti-arrhythmic drugs and/or more frequent check-ups of the thyroid status should be taken into consideration in patients at higher risk, i.e. women with positive antithyroperoxidase antibodies and goiter. If amiodarone treatment is considered necessary in the patients at a high risk of developing thyroid dysfunction, regular check-ups of the thyroid status and timely treatment of thyroid dysfunction are essential.
